COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ Curasight A/S Curasight or the Company – has today resolved on a new issue of shares with preferential rights for the Company s existing.
Preclinical studies show uTREAT® effective in treating non-small cell lung cancer Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis.
Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) announces today that the previously announced results from the investigator-initiated phase II study using uPAR-PET (uTRACE®) in primary brain cancer have been presented in an oral presentation at the World Molecular Imaging Congress (WMIC) 2023 in .
Positive results in uPAR-PET/MR Phase II study in brain cancer: Curasight prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Copenhagen, Denmark, 26 May 2023 - Curasight A/S hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company s Interim Report Q1 2023 at HC. | May 26, 2023